


Anticancer agent 109

Cat. No.:	HY-149092
CAS No.:	2097497-16-8
Molecular Formula:	C ₁₉ H ₁₅ N ₃ O ₂
Molecular Weight:	317.34
Target:	TAM Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Anticancer agent 109 (compound 6-15) is an inhibitor of the Gas6-Axl axis with anti-cancer activity. Anticancer agent 109 inhibits the expression of Gas6 and Axl, and the expression p-PI3K and p-AKT in cancer cells, leads to G1 phase arrest and promotes cancer cells apoptosis, and inhibits tumor growth significantly in nude mouse tumor bearing models ^[1] .																		
IC₅₀ & Target	Axl																		
In Vitro	<p>Anticancer agent 109 (10 μM, 48 h) inhibits of Gas6 and Axl in A549, inhibits of Gas6-Axl axis related proteins, increases the sub-G1 fraction and promotes of late stage apoptosis without altering DNA synthesis in PANC-1^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>MCF-7; PANC-1; MDA-MB-231 ; HT-29 ; DU145 ; U937 ; A549 ; PANC-1</td> </tr> <tr> <td>Concentration:</td> <td>30 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited the growth of cancer cells, and was up to 20-fold safer against normal cells and up to 5.4-fold more active than Sunitinib against the cancer cells. Inhibited growth with IC₅₀s of 2.0 μM (MCF-7); 2.8 μM (MDA-MB-231); 4.6 μM (HT-29); 1.1 μM (DU145); 6.7 μM (U937); 4.2 μM (A549); 4.0 μM (PANC-1).</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>PANC-1</td> </tr> <tr> <td>Concentration:</td> <td>1 μM , 5 μM , 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 h</td> </tr> <tr> <td>Result:</td> <td>Increased the sub-G1 fraction and induced late apoptosis.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>A549; PANC-1</td> </tr> </table>	Cell Line:	MCF-7; PANC-1; MDA-MB-231 ; HT-29 ; DU145 ; U937 ; A549 ; PANC-1	Concentration:	30 μM	Incubation Time:	48 h	Result:	Inhibited the growth of cancer cells, and was up to 20-fold safer against normal cells and up to 5.4-fold more active than Sunitinib against the cancer cells. Inhibited growth with IC ₅₀ s of 2.0 μM (MCF-7); 2.8 μM (MDA-MB-231); 4.6 μM (HT-29); 1.1 μM (DU145); 6.7 μM (U937); 4.2 μM (A549); 4.0 μM (PANC-1).	Cell Line:	PANC-1	Concentration:	1 μM , 5 μM , 10 μM	Incubation Time:	48 h	Result:	Increased the sub-G1 fraction and induced late apoptosis.	Cell Line:	A549; PANC-1
Cell Line:	MCF-7; PANC-1; MDA-MB-231 ; HT-29 ; DU145 ; U937 ; A549 ; PANC-1																		
Concentration:	30 μM																		
Incubation Time:	48 h																		
Result:	Inhibited the growth of cancer cells, and was up to 20-fold safer against normal cells and up to 5.4-fold more active than Sunitinib against the cancer cells. Inhibited growth with IC ₅₀ s of 2.0 μM (MCF-7); 2.8 μM (MDA-MB-231); 4.6 μM (HT-29); 1.1 μM (DU145); 6.7 μM (U937); 4.2 μM (A549); 4.0 μM (PANC-1).																		
Cell Line:	PANC-1																		
Concentration:	1 μM , 5 μM , 10 μM																		
Incubation Time:	48 h																		
Result:	Increased the sub-G1 fraction and induced late apoptosis.																		
Cell Line:	A549; PANC-1																		

Concentration:	10 μ M
Incubation Time:	48 h
Result:	Inhibited Gas6 and Axl in A549 and PANC-1 cell, increased the expression ratio of Bax/Bcl-2 and inhibited p-PI3K and p-AKT in PANC-1 cell.
RT-PCR ^[1]	
Cell Line:	PANC-1
Concentration:	3 μ M ;5 μ M 10 μ M
Incubation Time:	48 h
Result:	Inhibited Gas6 and Axl.

In Vivo

Anticancer agent 109 (3 mg/kg, intraperitoneal injection, A549 tumor model for 31 days, PANC-1 tumor model for 85 days, six times a week) reduced tumor size and weight significantly in xenograft models of nude mice^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	A549 or PANC-1 xenografted in BALB/c-nu mice ^[1] .
Dosage:	1 mg/kg; 3 mg/kg
Administration:	Intraperitoneal injection (i.p.) 6 times a week
Result:	Promoted tumor regression to around a quarter with 1 mg/kg, smaller but not eliminated with 3 mg/kg in A549 models. Promoted tumor regression to around a quarter with 3 mg/kg in PANC-1 models.

REFERENCES

[1]. Bae D, et al. Antitumor effect of 3-(quinolin-2-ylmethylene)-4,6-dimethyl-5-hydroxy-7-azaaxindole down-regulating the Gas6-Axl axis. Eur J Med Chem. 2023 May 5;251:115274.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA